Abstract
Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have